GlucoTrack (GlucoTrack) Debt-to-Asset : 0.04 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is GlucoTrack Debt-to-Asset?

GlucoTrack's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. GlucoTrack's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.20 Mil. GlucoTrack's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $4.91 Mil. GlucoTrack's debt to asset for the quarter that ended in Dec. 2023 was 0.04.

GlucoTrack Debt-to-Asset Historical Data

The historical data trend for GlucoTrack's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlucoTrack Debt-to-Asset Chart

GlucoTrack Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.35

0.03

0.04

0.08

0.04

GlucoTrack Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.08	0.15	0.02	0.03	0.04

Competitive Comparison of GlucoTrack's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, GlucoTrack's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlucoTrack's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GlucoTrack's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where GlucoTrack's Debt-to-Asset falls into.

GlucoTrack Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

GlucoTrack's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0.196)	/	4.905
	=	0.04

GlucoTrack's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0.196)	/	4.905
	=	0.04

GlucoTrack (NAS:GCTK) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

GlucoTrack Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of GlucoTrack's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

GlucoTrack (GlucoTrack) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GlucoTrack Inc (NAS:GCTK) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Route 17 North, Suite 800, Rutherford, New Jersey, NJ, USA, 07070

Website

https://www.glucotrack.com

GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It also focuses on developing a wireless module for transmission of measurement data captured by the GlucoTrack model DF-F to a cloud-based server.

Executives

James S Cardwell	officer: Chief Financial Officer	CLINTON SQUARE, 75 S. CLINTON AVE., SUITE 510, ROCHESTER NY 14604
Erin Catherine Carter	director	301 RTE 17 NORTH, STE. 800, RUTHERFORD NJ 07070
Allen Danzig	director	301 RT 17 NORTH, SUITE 800, RUTHERFORD NJ 07070
Shimon D Rapps	director	C/O ANDREW GARRETT, INC., 52 VANDERBILT AVENUE SUITE 510, NEW YORK NY 10017
Drew Sycoff	director	C/O ANDREW GARRETT INC, 52 VANDERBILT AVENUE - 20TH FLOOR, NEW YORK NY 10017
David Podwalski	officer: Chief Commercial Officer	19 HA'YAHALOMIM ST., P.O. BOX 12163, ASHDOD L3 7760049
Michael Hauck	director	19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
John A Graham	director, officer: Chief Executive Officer	19 HA'YAHALOMIM STREET, P.O. BOX 12163, ASHDOD L3 7760049
Sami Sassoun	officer: Chief Financial Officer	39-06 ACKERMAN DRIVE, FAIR LAWN L3 7760049
Philip Darivoff	director	1 FARMSTEAD ROAD, SHORT HILLS NJ 07078
Revan Schwartz	director	19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
Angela Strand Boydston	director	C/O AEROGEN, INC., 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Leslie Seff	director	PO BOX 59, 40 HELLBROOK LANE, ULSTER PARK NY 12487
Eran Hertz	officer: Chief Financial Officer	C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L3 78100
Israel B. Ehrlich	director	C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L378100